Patents by Inventor Robert John Watson

Robert John Watson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydroxamic and carboxylic acid derivatives
    Patent number: 6469020
    Abstract: The invention relates to hydroxamic and carboxylic acid derivatives. Compounds of the formula: are disclosed. These compounds are useful for the treatment of diseases mediated by inhibitors of matrix metalloproteinase, ADAM, ADAM-TS enzymes, and or INF&agr;-mediated diseases including degenerative diseases and certain cancers.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: October 22, 2002
    Assignee: Darwin Discovery, Ltd.
    Inventors: Duncan Batty, Verity Margaret Sabin, Robert John Watson, Hazel Joan Dyke, Andrew Sharpe, Richard John Davenport, David Alan Owen, Andrew Douglas Baxter
  • Hydroxamic and carboxylic acid derivatives
    Patent number: 6465468
    Abstract: The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with matrix metalloproteinase, ADAM or ADAM-TS enzymes, a condition that is mediated by TNF &agr; or a condition involving a membrane-shedding event that is mediated by a metalloproteinase. Compounds of the invention are of formula I (B)2N—X—(CH2)m—W—(CR1R2)n—COY  (I) wherein n=0 or 1; m=0 or 1; X is S(O)1-2; Y is OH or NHOH; W is aryl or heteroaryl; and the other groups are as defined herein.
    Type: Grant
    Filed: March 22, 2000
    Date of Patent: October 15, 2002
    Assignee: Darwin Discovery Limited
    Inventors: Andrew Douglas Baxter, David Alan Owen, Duncan Batty, Robert John Watson
  • Hydroxamic acid derivatives as matrix metalloproteinase (mmp) inhibitors
    Patent number: 6462042
    Abstract: Compounds having therapeutic utility are of formula (I) wherein B1, B2, R1 and R2 are each various sub-stituents, or R1 and R2 together form a ring.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: October 8, 2002
    Assignee: Darwin Discovery Limited
    Inventors: David Alan Owen, Andrew Douglas Baxter, Robert John Watson, John Gary Montana
  • Hydroxamic acid derivatives
    Patent number: 6455531
    Abstract: Compounds having therapeutic utility are of the formula wherein NB2 is heterocycloalkyl and R1 and R2 are each various substituents or a cyclic group.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: September 24, 2002
    Assignee: Darwin Discovery, Ltd.
    Inventors: David Alan Owen, Andrew Douglas Baxter, Robert John Watson, Duncan Robert Hannah, John Gary Montana
  • Hydroxamic and carboxylic acid derivatives
    Publication number: 20020022635
    Abstract: A phacologically actve compound of forula (1) 1
    Type: Application
    Filed: May 15, 2001
    Publication date: February 21, 2002
    Inventors: Duncan Robert Hannah, Hazel Joan Dyke, Robert John Watson, John Fraser Keily, Andrew Douglas Baxter
  • Hydroxamic and carboxylic acid derivatives
    Publication number: 20020013333
    Abstract: A pharmacologically active compound of formula (I) 1
    Type: Application
    Filed: May 15, 2001
    Publication date: January 31, 2002
    Inventors: Duncan Batty, Verity Margaret Sabin, Robert John Watson, Hazel Joan Dyke, Andrew Sharpe, Richard John Davenport, David Alan Owen, Andrew Douglas Baxter
  • Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
    Patent number: 6187924
    Abstract: Compounds of formula (I) are useful as therapeutic agents, by virtue of having MMP and TNF inhibitory activity.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: February 13, 2001
    Assignee: Darwin Discovery, Ltd.
    Inventors: Andrew Douglas Baxter, David Alan Owen, John Gary Montana, Robert John Watson
  • Peptidyl compounds
    Patent number: 6180611
    Abstract: Compounds of general formula (I): have utility as inhibitors of matrix metalloproteinases and TNF.
    Type: Grant
    Filed: May 20, 1999
    Date of Patent: January 30, 2001
    Assignee: Darwin Discovery, Ltd.
    Inventors: John Montana, Andrew Douglas Baxter, David Alan Owen, Robert John Watson, Neil Phillipson
  • Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
    Patent number: 6118001
    Abstract: Disclosed are hydroxamic and carboxylic acid derivatives which are useful inhibitors of matrix metalloproteinase and/or TNF.alpha.-mediated diseases, including degenerative diseases and certain cancers.
    Type: Grant
    Filed: August 7, 1997
    Date of Patent: September 12, 2000
    Assignee: Darwin Discovery, Ltd.
    Inventors: David Alan Owen, John Gary Montana, John Fraser Keily, Robert John Watson, Andrew Douglas Baxter
  • Peptidyl compounds having MMP and TNF inhibitory activity
    Patent number: 6114372
    Abstract: Compounds of formula (I) having MMP and TNF inhibitory activity.
    Type: Grant
    Filed: October 2, 1998
    Date of Patent: September 5, 2000
    Assignee: Darwin Discovery Limited
    Inventors: Andrew Douglas Baxter, David Alan Owen, John Gary Montana, Robert John Watson, John Fraser Keily
  • Peptidyl compounds having MMP and TNF inhibitory activity
    Patent number: 6090840
    Abstract: The subject invention concerns mercaptoalkylacyl compounds of formula (I): ##STR1## The compounds of the subject invention can be used to inhibit matrix metalloproteinases and/or TNF.alpha.- and L-selectin sheddase-mediated diseases including degenerative diseases and cancers. The subject invention also concerns methods of using the compounds of the invention to treat or prevent conditions associated with matrix metalloproteinases or that are mediated by TNF.alpha. or L-selectin sheddase.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: July 18, 2000
    Assignee: Darwin Discovery Limited
    Inventors: Andrew Douglas Baxter, David Alan Owen, John Gary Montana, Robert John Watson, John Fraser Keily
  • Peptidyl compounds
    Patent number: 5994312
    Abstract: Compounds of general formula (I): ##STR1## have utility as inhibitors of matrix metalloproteinases and TNF.
    Type: Grant
    Filed: July 30, 1998
    Date of Patent: November 30, 1999
    Assignee: Darwin Discovery, Ltd.
    Inventors: John Montana, Andrew Douglas Baxter, David Alan Owen, Robert John Watson, Neil Phillipson
  • Quinolones and their therapeutic use
    Patent number: 5792774
    Abstract: A compound of formula (I) ##STR1## or a pharmaceutically-acceptable salt, solvate or hydrate thereof.
    Type: Grant
    Filed: February 21, 1997
    Date of Patent: August 11, 1998
    Assignee: Chiroscience Limited
    Inventors: Alan Findlay Haughan, Steven Colin Beasley, John Gary Montana, Robert John Watson
  • Hypoxanthine and guanine compounds
    Patent number: 5736549
    Abstract: Compounds of formula I ##STR1## where n=0-2;R.sup.1 is H, NH.sub.2 or a halogen;R.sup.2 is H or NH.sub.2 ;R.sup.3 is any of the four groups ##STR2## where m=0 or 1; andX is O, NR.sup.5, or S(O).sub.0-2 and, in group (b), the X's may be the same or different.Compounds of the invention have utility as inhibitors of purine nucleoside phosphyorylase (PNP).
    Type: Grant
    Filed: October 5, 1995
    Date of Patent: April 7, 1998
    Assignee: Chiroscience Limited
    Inventors: Steven Colin Beasley, Alan Findlay Haughan, John Montana, Robert John Watson